J&J reports 1% profit rise despite lower sales
October 13, 2009 at 12:08 PM EDT
Johnson & Johnson reported a 1% rise in third-quarter earnings, but its sales performance was tempered by declining sales of three of its top-selling prescription drugs, Topamax, Razadyne and Risperdal, due to increased generic competition.
